A session at the AACR Annual Meeting 2015. Photo by AACR/Todd Buchanan.

The AACR Annual Meeting 2015 took place April 18-22 in Philadelphia, Pennsylvania.

Inhibitor promotes chemosensitization in CLL

Print Friendly, PDF & Email


CLL_BM.jpg
CLL cells

A DNA-dependent protein kinase (DNA-PK) inhibitor can sensitize chronic lymphocytic leukemia (CLL) cells to chemotherapy, according to preclinical research. The inhibitor, NDD0004, sensitized CLL cells—even those from patients with high-risk cytogenetics—to treatment with mitoxantrone. However, not all CLL samples were sensitive to treatment, so researchers are now trying to determine which patients might... [Read Article]

Print Friendly, PDF & Email

Study helps explain how drug fights DLBCL

Print Friendly, PDF & Email


researchers_microscope_NCI_Rhoda_Baer_230.jpg
Researchers in the lab
Photo by Rhoda Baer

The tumor microenvironment may play a key role in treatment with CUDC-427, according to researchers. Their experiments showed that certain diffuse large B-cell lymphoma (DLBCL) cell lines were sensitive to CUDC-427, and others were not. However, co-culturing with stromal cells or TNF family ligands made resistant... [Read Article]

Print Friendly, PDF & Email

Inhibitor may benefit certain ALL patients

Print Friendly, PDF & Email


lab_mouse_240.jpg
Lab mouse

Results of preclinical research suggest the BCL-2 inhibitor ABT-199 (venetoclax) may be effective in certain pediatric patients with acute lymphoblastic leukemia (ALL). In xenograft models of various ALL subtypes, ABT-199 produced an objective response rate below 30%. However, additional analyses unearthed information that could potentially help us identify which ALL patients might respond... [Read Article]

Print Friendly, PDF & Email

Agent preferentially targets FLT3-ITD AML

Print Friendly, PDF & Email


AML_in_bone_marrow_240.jpg
AML cells in the bone marrow

Preclinical research suggests a novel agent has preferential activity in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations. The agent, VNLG-152, proved more cytotoxic in AML cell lines and patient samples with FLT3-ITD than in samples and cell lines with wild-type FLT3. Exactly... [Read Article]

Print Friendly, PDF & Email

Defining the role of TAMs in DLBCL

Print Friendly, PDF & Email


macrophage_in_a_mouse_Flickr_230.jpg
A macrophage stretching its
pseudopodia to engulf particles

New research suggests the prognostic value of tumor-associated macrophages (TAMs) is disease-specific as well as treatment-specific. Investigators set out to determine if TAMs have a negative prognostic impact in diffuse large B-cell lymphoma (DLBCL), as previous studies produced conflicting results. The team found that higher TAM... [Read Article]

Print Friendly, PDF & Email

Susceptibility to 2nd cancers in WM/LPL survivors

Print Friendly, PDF & Email


AACR_2015_man_registration_240_brighter.jpg
AACR Annual Meeting 2015

A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) and other malignancies. Study investigators looked at patients diagnosed with WM or LPL over a 20-year period and found about a 50% excess of second primary cancers in this population. The patients... [Read Article]

Print Friendly, PDF & Email

MKIs can overcome resistance in CML

Print Friendly, PDF & Email


AACR_2015_banner_edited_240.jpg
AACR Annual Meeting 2015

Two multikinase inhibitors (MKIs) can treat chronic myeloid leukemia (CML) that is resistant to other inhibitors, according to preclinical research. A series of in vitro experiments showed that the MKIs, sorafenib and axitinib, can overcome treatment resistance mediated by hyperactivation of the Src kinase Lyn, overexpression of the docking protein Gab2,... [Read Article]

Print Friendly, PDF & Email

Molecule increases TRAIL expression to fight NHL

Print Friendly, PDF & Email


AACR_2015_hashtag_220.jpg
Inside the Pennsylvania
Convention Center, site of the
AACR Annual Meeting 2015

When current treatment approaches failed to save a young patient with non-Hodgkin lymphoma (NHL), a researcher from The Children’s Hospital of Philadelphia was driven to investigate new therapeutic options. The investigation led the researcher, Mala Talekar, MBBS, to ONC201 (formerly TIC10),... [Read Article]

Print Friendly, PDF & Email

CDK inhibitor proves active against AML, ALL

Print Friendly, PDF & Email


lab_mouse_245.jpg
Lab mouse

Preclinical research suggests a cyclin-dependent kinase (CDK) inhibitor is active against acute leukemias, particularly those with mixed-lineage leukemia rearrangements (MLL-r). CYC065 selectively inhibits CDK2, which drives cell-cycle transition and activates major DNA double-strand break repair pathways; CDK5, which drives metastatic spread; and CDK9, which regulates the transcription of genes important for the proliferation... [Read Article]

Print Friendly, PDF & Email

‘Watch and wait’ may be inadvisable for CLL

Print Friendly, PDF & Email


AACR_2015_man_registration_240_brighter.jpg
Registration area at AACR 2015

Withholding treatment from chronic lymphocytic leukemia (CLL) patients because they are of advanced age and have comorbidities may not be in their best interest, according to research presented at the AACR Annual Meeting 2015. Most of the patients in this prospective, single-center study had 2 or more comorbidities, and their... [Read Article]

Print Friendly, PDF & Email

EBV-CTLs produce durable responses in EBV-LPD

Print Friendly, PDF & Email


EBV-infected_cell_210.jpg
An EBV-infected cell (green)
among uninfected cells (blue)
Image courtesy of NIH/
Benjamin Chaigne-Delalande

Cytotoxic T lymphocytes designed to target Epstein-Barr virus (EBV-CTLs) can elicit durable responses in patients with EBV–associated lymphoproliferative disorder (EBV-LPD), according to data presented at the AACR Annual Meeting 2015. Results from two trials showed that EBV-CTLs... [Read Article]

Print Friendly, PDF & Email